Evolus, Inc. EOLS
Evolus, Inc. (Nasdaq: EOLS) is a dermatology drug developer. Its lead program, Jeuveau (prabotulinumtoxinA-xvfs), is marketed for temporary improvement in appearance of moderate to severe glabellar lines (aesthetic). Its next catalyst on record is Evolysse Sculpt: FDA PMA approval (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Evolysse Sculpt — FDA PMA approval (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Jeuveau | glabellar lines (aesthetic) | protein/peptide | Approved |
| Evolysse Form / Smooth (HA gel, device) | wrinkles and folds / nasolabial folds | device-combination | NA_NON_THERAPEUTIC |
| Evolysse Sculpt (HA gel, PMA) | mid-face volume | device-combination | NA_NON_THERAPEUTIC |
| Evolysse Lips (HA gel, PMA) | lip fullness | device-combination | NA_NON_THERAPEUTIC |
| Profhilo (IBSA, HA skin-quality product) | skin quality (aesthetic) | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved dermatology companies
- Journey Medical Corp DERM
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.